Pfizer Animal Health Essay -- Business Marketing Case Study, solution

Pfizer entered the animal health pains in the early 1950s. Today, Pfizer creature Health products argon sold to veterinarians, lineage producers, and horse and darling owners in more than 140 countries around the conception and used in more than 30 species. Pfizer sentient being Health is perpetrate to providing high-quality, research-based health products for livestock and companion animals. The company continues to invest more in research and development than any other animal health company. This offers opportunities for real(a) fruit and internal synergy. Pfizer has more new animal health products in its research pipeline today than at any other judgment of conviction in its history. Their products include anti-inflammatory, anti-infectious, and anti-parasitic pharmaceutical medicines, vaccines and lean additives. These products are used by cattle, swine, and poultry industries, as well as, veterinarians serving both the livestock and pet markets. The animal health seg ment of Pfizer accounts for approximately 10% of their total revenues. ) Pfizer Animal Health revenues were $1,314 million in 1998. Some of Pfizers top change animal health products are Rimadyl, Anipryl, Dectomax, and RespiSure. The animal health segment is served in manufacturing by the 35 production plants around the world. Their products are sold done veterinarians, drug wholesalers, retail outlets, distributors, and directly to users. Animal Health gross revenues filiationd 1% to 1.3 billion in 1998. (Note Appendix) This decrease is due to continuing weaknesses in the U.S. livestock market, the poor Asian economy, and the unfavorable effects of foreign exchange. This decline was offset by growth of Pfizer products the cattle endectocide Dectomax, the canine anti-arthritic Rimadyl, and the swine vaccine RepiSure. Pfizer is among the tip suppliers of companion animal vaccines, a $500 million market worldwide. They choose over 43 animal health product candidates in clinical de velopment. Pfizers Animal Health markets several feed supplements for large animals. devote supplement product sales slowed in 1998, due in pop out to regulatory issues, market conditions, and competitive pressures.Pfizers goal for both its ancestry units is to meet the needs and exceed the expectations of all their customers. They achieve this with ongoing instauration through state-of-the-art research and development, ... ...s small, medium, large, and extra large coolers to accommodate shipments ranging in size. Government regulations are a large threat to our company. In celestial latitude 1998, the Council of European Agricultural Ministers voted to ban the use of Pfizers antibiotic feed additive, STAFAC, throughout the European Union. It is regulations like these that can stunt our sales growth in both of our business segments. FDA requirements and reviews have increased the amount of duration and money necessary to develop new products and bring them to market. Our inte rnational businesses are subject to a number of risks that are inherent in carrying on business in other countries. Some government-imposed restraints may include laws on pricing or reimbursements for use of products. Another threat to Pfizers Animal Health segment is competition. Principal methods of competition in this marketplace pull up stakes depending on the particular product, but are mainly product innovation, service, price, quality, and trenchant promotion to veterinary professionals and consumers. Pfizer is the leader in the animal health industry today. Some of their main competitors are Merck, Alpharma Inc, and Wingo Inc.